Children’s Hospital Los Angeles (CHLA) recently joined other prominent U.S. pediatric centers in the Xplore-2 clinical research study. The medical institutions that may enroll patients in the Xplore-2 Early Feasibility Study also include: Boston Children’s Hospital, Children’s Healthcare of Atlanta, Children’s Hospital of Philadelphia and New York Presbyterian/Columbia University Medical Center.

Xplore-2 is an Early Feasibility Study evaluating Xeltis’ novel restorative pulmonary heart valve for Right Ventricular Outflow Tract (RVOT) reconstruction. Xeltis’ restorative pulmonary valve is an investigational device not approved for use in the United States.

Every year in the USA, approximately 40,000 children are born with congenital heart disease (CHD). Around 15-20 percent of these children have congenital defects of the RVOT. Defective RVOTs require surgical intervention, which often involves replacement of the pulmonary valve.

For more information on the Xplore-2 study visit:

For more information on current and upcoming treatment options for RVOT reconstruction view the Mended Little Hearts webinar: